The drug hydroxyurea has been life-changing for those who are able to use it (it is not effective for all types of sickle cell disease), yet many people who are eligible are not using hydroxyurea. This group of resources have been used by providers to share information with patients about the benefits and risks of using hydroxyurea.
- Patient Education
- Dosing Guidelines
- Journal Article: "Improved Hydroxyurea Effect With the Use of Text Messaging in Children With Sickle Cell Anemia" (created by TN TDP)
These resources were developed through the Working to Improve Sickle Cell Healthcare (WISCH) projects. WISCH is NICHQ’s multi-year umbrella name for two sickle cell projects, the Sickle Cell Disease Treatment Demonstration Program (SCDTDP) and the Sickle Cell Disease Newborn Screening Program (SCDNBSP). As the National Coordinating Center for these programs, NICHQ is happy to share guidance, tools and resources that teams from around the country have created, tested or used to improve care for patients with sickle cell disease.